AbbVie Reaffirms Previously Issued 2024 Adjusted EPS Guidance Of $11.05-$11.25 (Versus Consensus Of $11.21) Which Includes $0.42/Share (Earlier $0.32/Share) Dilutive Impact Related To The Immunogen Acquisition And Pending Cerevel Deal
Portfolio Pulse from Benzinga Newsdesk
AbbVie has reaffirmed its adjusted EPS guidance for 2024 at $11.05-$11.25, aligning with the consensus of $11.21. This forecast now includes a $0.42 per share dilutive impact from the Immunogen acquisition and the pending Cerevel deal, an increase from the previously estimated $0.32 per share.
February 12, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AbbVie reaffirms its 2024 adjusted EPS guidance, now including a higher dilutive impact from acquisitions, indicating strategic investments.
AbbVie's reaffirmation of its 2024 EPS guidance, despite a higher dilutive impact from its acquisitions, suggests confidence in its strategic investments and their long-term benefits. The alignment with consensus estimates may stabilize investor sentiment, but the increased dilutive impact could raise concerns about short-term earnings pressure. Overall, the impact is neutral as the market absorbs the implications of the strategic acquisitions against the backdrop of AbbVie's financial strength and future growth prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100